Welcome to our dedicated page for Zura Bio SEC filings (Ticker: ZURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Zura Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Zura Bio's regulatory disclosures and financial reporting.
Zura Bio Ltd (ZURA) received a notice under Rule 144 that director Someit Sidhu intends to sell common shares. The planned transaction involves 50,000 common shares through Morgan Stanley Smith Barney LLC, with an aggregate value of $287,712.50, currently associated with NASDAQ trading on 08/18/2026. The shares are tied to a stock option exercise for cash from the issuer on the same date. Over the prior three months, the same person reported additional sales of ZURA common stock.
Someit Sidhu, an affiliate of ZURA, has filed a notice of proposed sale of restricted or control securities. The filing covers a planned sale of 27,000 shares of common stock of ZURA on or about 08/17/2026, to be executed for cash through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, in connection with a stock option exercise. The notice also lists prior sales during the past three months totaling 40,000 shares for $220,540.00 on 08/14/2026 and 51,000 shares for $287,043.30 on 08/13/2026.
Zura Bio Limited furnished a corporate presentation dated August 17, 2026 for use at conferences and investor meetings. The presentation is included as Exhibit 99.1 and can be accessed via the News & Events section of the company’s investor relations website.
The information in this communication, including Exhibit 99.1, is furnished under Item 7.01 and is explicitly stated not to be deemed “filed” for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act, nor incorporated by reference into other SEC filings except where specifically referenced.
Someit Sidhu has filed to sell 40,000 shares of Common Stock of ZURA through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated aggregate value of $220,540.00, to be sold on or after August 14, 2026 on NASDAQ.
The filing also notes a prior stock option exercise on August 13, 2026 related to 40,000 shares and a separate sale of 51,000 shares of Common Stock on August 13, 2026 for $287,043.30.
Zura Bio Limited reported second quarter 2026 results and highlighted progress in its immunology pipeline centered on tibulizumab. Enrollment in both Phase 2 trials completed above target, with 247 participants in hidradenitis suppurativa (TibuSHIELD) and 91 in systemic sclerosis (TibuSURE). Topline data are expected in Q4 2026 and the first half of 2027, respectively, and a Phase 2 PMR study (NEXUS‑PMR) is planned by year-end 2026.
Cash and cash equivalents were $205.1 million as of June 30, 2026, up from $109.4 million at year-end 2025, and the company expects this to fund planned operations through at least the end of 2028. Second quarter 2026 R&D expense was $20.7 million and G&A expense was $8.6 million. Net loss for the quarter was $26.3 million, or $0.21 per share, compared with $16.0 million, or $0.17 per share, a year earlier. Shares outstanding were 95.4 million Class A ordinary shares as of June 30, 2026.
Zura Bio Limited is a clinical-stage biotechnology company focused on autoimmune and inflammatory diseases, advancing lead antibody tibulizumab through Phase 2 trials in hidradenitis suppurativa and diffuse cutaneous systemic sclerosis, with additional programs in torudokimab and crebankitug under evaluation.
For the three months ended June 30, 2026, Zura reported a net loss of $26.3 million, and for the six months a net loss of $50.5 million, reflecting higher research and development spending as Phase 2 programs ramped. Research and development expenses rose to $20.7 million in the quarter and $35.5 million year-to-date, largely driven by tibulizumab clinical trial and manufacturing costs and increased R&D headcount. General and administrative expenses were $8.6 million in the quarter and $19.4 million for the six months.
Cash and cash equivalents were $205.1 million as of June 30, 2026, up from $109.4 million at year-end 2025, primarily due to the February 2026 equity offering, which generated approximately $134.6 million in net proceeds from issuing 21.2 million Class A Ordinary Shares and 1.8 million pre-funded warrants. Total assets were $213.4 million and shareholders’ equity $197.1 million, with management stating current liquidity is sufficient to fund operations through at least the end of 2028.
Zura Bio Limited furnished an updated corporate presentation dated July 1, 2026 for use at upcoming conferences and investor meetings. The presentation is provided as Exhibit 99.1 and is also available in the News & Events section of the company’s investor website.
The information is furnished under Item 7.01 of Form 8-K and is not deemed filed for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act, nor incorporated by reference into other SEC filings unless specifically referenced.
Zura Bio Ltd reports that officer Mathew Marlyn Teresa, VP and Principal Accounting Officer, holds 129,182 Class A ordinary shares, including 32,296 shares underlying restricted stock units that vest in full on May 18, 2027 if continuous service is maintained.
He also holds several employee share options over Class A ordinary shares, including 66,220 shares at an exercise price of $6.03, 81,150 shares at $1.20, 90,000 shares at $3.38, and additional tranches at a $0.00 exercise price, with expirations between 2032 and 2036. The option awards vest over time, with initial vesting dates on March 15, 2024, June 18, 2025, February 27, 2026 and April 1, 2027, subject to his continued service.
Zura Bio Ltd director Jennifer Jarrett received a grant of share options covering 51,000 Class A Ordinary Shares. The options have an exercise price of $3.62 per share and expire on June 17, 2036. Following this grant, she holds options on 51,000 shares directly.
The option award vests in twelve substantially equal monthly installments over one year starting June 17, 2026. Any remaining unvested portion will vest immediately before the next annual shareholder meeting after the grant date, subject to her continued service through each vesting date.